Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Stopped early · Phase 1/Phase 2

Conditions studied: Acute Graft Versus Host Disease

In brief

Phase II efficacy evaluation, phase I/II efficacy and toxicity trial of recombinant human keratinocyte growth factor for the treatment of steroid refractory gastrointestinal graft versus host disease.

Key facts

Study ID

NCT00038792

Run by

M.D. Anderson Cancer Center

People needed

7

Starts

2000-10-01

Expected to finish

2003-01-01

Last updated by the study team

2012-08-02

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients post allogeneic bone marrow transplant with watery diarrhea progressed on 2mg/kg of steroids after 3 days or failed to improve after 5 days.
• Patients may have skin or liver involvement with graft versus host disease.
• Patients should not have any infections etiology for diarrhea.

You may not qualify if…

• None

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.